A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Phase 2TerminatedNCT00282763

Merck Sharp & Dohme LLC12 enrolled

Overview

The purpose of this Study is to test the Safety and Effectiveness of MK0686 in relieving neuropathic (chronic) pain as experienced by patients with Postherpetic Neuralgia (Also Know as PHN or Post Shingles Pain). This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Neuralgia, Postherpetic

Interventions

MK0686DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of postherpetic neuralgia with pain having lasted at least 6 months * Able to complete study questionnaires, patient diary, and comply with daily study medication * Patient is not satisfied with current treatment for pain control Exclusion Criteria: * Pregnant or nursing female * History of evidence of a condition that in the opinion of the investigator, may interfere with the study results (e.g., diabetic neuropathy of fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease)

Outcomes

Primary Outcomes

proprietary information - exploratory (non-confirmatory) trial

Secondary Outcomes

proprietary information - exploratory (non-confirmatory) trial

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.